Physician profile
Edwin W Hoeper
NPI 1962537712
$3,796.06
in general payments reported to CMS, 2019-2025
20 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $590 · 2021: $661 · 2022: $861 · 2023: $764 · 2024: $523 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,394 · Education: $12.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,393.63 |
| Education | $12.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $833.05 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $636.01 | 2020-2025 | Nuedexta, Rexulti |
| Merck Sharp & Dohme LLC | $377.40 | 2020-2023 | Belsomra |
| Bausch Health US, LLC | $314.35 | 2019-2023 | Aplenzin |
| Abbvie INC. | $311.79 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $278.06 | 2019-2024 | Trintellix |
| Allergan, INC. | $261.75 | 2019-2020 | |
| Lundbeck LLC | $150.49 | 2022-2024 | Rexulti |
| Eisai INC. | $105.53 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $97.39 | 2022-2025 | Quviviq, Quviviq |
| Janssen Pharmaceuticals, INC | $87.70 | 2023-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $86.61 | 2019-2023 | Hetlioz, Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.16 | 2020-2023 | |
| Axsome Therapeutics, INC. | $52.51 | 2023 | Auvelity |
| Almatica Pharma LLC | $40.82 | 2023-2024 | Loreev Xr, Sertraline Hcl |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $19.74 | 2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $18.44 | 2022 | |
| Harmony Biosciences LLC | $15.88 | 2024 | |
| Lilly USA, LLC | $14.74 | 2025 | Kisunla |
| Corium, LLC | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Hoeper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.